Viruses cannot replicate by themselves. Instead, they rely on the host for almost all their
replicative functions. Similarly, many viruses are unable to cause damage without the host …

Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …

Abstract Type 1 Interferons (IFNs) have been associated with positive effects on
Coronaviruses. Previous studies point towards the superior potency of IFNβ compared to …

Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for
COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory …

In the originally published article, the imprecise wording of a sentence implied that IL-6
blockade had been approved by the FDA for treatment of COVID-19. This has now been …

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects both people and
animals and may cause significant respiratory problems, including lung illness: Corona …

Coronavirus disease 2019 (COVID‐19) has spread rapidly around the world since its
emergence in humans last December. Previous studies suggested that numerous markers …

In the context of COVID-19 pandemic and growing tensions worldwide regarding healthcare
facilities, there is an urgent need for effective treatments likely to reduce the crunch of ICU …

To the Editor, We read with interest the study by Luo et al 1 that evaluates the efficacy of
tocilizumab (antibody against interleukin‐6 [IL‐6]) in patients with coronavirus disease 2019 …

For the initial phase of pandemic of coronavirus disease 2019 (COVID-19), repurposing
drugs that in vitro inhibit severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) …